We are live on ! Find out more
THRX

Theseus Pharmaceuticals, Inc. Common Stock
THRX

Delisted

THRX was delisted on the 13th of February, 2024.

Back to rankings

1 hedge funds and large institutions have $0 invested in Theseus Pharmaceuticals, Inc. Common Stock in 2024 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 69 closing their positions.

New
Increased
Maintained
Reduced
Closed

99% less funds holding

Funds holding: 70 → 1 (-69)

100% less funds holding in top 10

Funds holding in top 10: 3 → 0 (-3)

100% less capital invested

Capital invested by funds: $146M → $0 (-$146M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 69

Holders
1
Holders Change
-69
Holders Change %
-98.57%
% of All Funds
0.01%
Holding in Top 10
–
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
1
Reduced
–
Closed
69
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
+$53.8K

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$71.7M
2
FCMV
Foresite Capital Management V
California
-$16.6M
3
TCM
Tang Capital Management
California
-$13.2M
4
FLSM
Frazier Life Sciences Management
California
-$8.58M
5
BlackRock
BlackRock
New York
-$5.77M
Name Holding Trade Value Shares
Change 		Change in
Stake
Charles Schwab
26
Charles Schwab
California
– -$228K -56,203 Closed
ETC
27
Exchange Traded Concepts
Oklahoma
– -$196K -48,510 Closed
SO
28
STRS Ohio
Ohio
– -$187K -46,300 Closed
Dimensional Fund Advisors
29
Dimensional Fund Advisors
Texas
– -$179K -44,145 Closed
Citadel Advisors
30
Citadel Advisors
Florida
– -$179K -44,098 Closed
Squarepoint
31
Squarepoint
New York
– -$169K -41,708 Closed
RhumbLine Advisers
32
RhumbLine Advisers
Massachusetts
– -$150K -37,155 Closed
Barclays
33
Barclays
United Kingdom
– -$130K -32,097 Closed
Bank of America
34
Bank of America
North Carolina
– -$115K -28,402 Closed
VF
35
Virtu Financial
New York
– -$107K -26,467 Closed
FLC
36
Fifth Lane Capital
Texas
– -$101K -25,000 Closed
JC
37
JBF Capital
Colorado
– -$94.7K -23,394 Closed
UBS Group
38
UBS Group
Switzerland
– -$90K -22,218 Closed
Walleye Capital
39
Walleye Capital
New York
– -$87.3K -21,552 Closed
CSS
40
Cubist Systematic Strategies
Connecticut
– -$75.3K -18,588 Closed
Two Sigma Advisers
41
Two Sigma Advisers
New York
– -$72.5K -17,900 Closed
Deutsche Bank
42
Deutsche Bank
Germany
– -$68.7K -16,961 Closed
AllianceBernstein
43
AllianceBernstein
Tennessee
– -$63.3K -15,620 Closed
Two Sigma Investments
44
Two Sigma Investments
New York
– -$57.2K -14,112 Closed
JP Morgan Chase
45
JP Morgan Chase
New York
– -$56.9K -14,052 Closed
SG Americas Securities
46
SG Americas Securities
New York
– -$54K -13,212 Closed
UOC
47
UBS O'Connor
Illinois
– -$50.7K -12,517 Closed
SPS
48
Susquehanna Portfolio Strategies
Pennsylvania
– -$45K -11,112 Closed
American Century Companies
49
American Century Companies
Missouri
– -$42.6K -10,514 Closed
Principal Financial Group
50
Principal Financial Group
Iowa
– -$41.4K -10,216 Closed
1
2
3

THRX Hedge Fund Activity: Q1 2024 in Review

1 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Theseus Pharmaceuticals, Inc. Common Stock (THRX) for Q1 2024, worth a combined $0 — down 100% from $146M a quarter earlier.

Sellers outnumbered buyers: 69 funds closed out of THRX and 0 opened new positions — a net loss of 69 holders — while 0 trimmed existing stakes and 1 added.

The largest buyer was Goldman Sachs, adding an estimated $53.8K. The largest seller was OrbiMed, exiting entirely with an estimated $71.7M sold.

  • 1 institutional investor held Theseus Pharmaceuticals, Inc. Common Stock (THRX) as of Q1 2024, down from 70 in Q4 2023.
  • Funds reported $0 of Theseus Pharmaceuticals, Inc. Common Stock stock for Q1 2024, down 100% quarter-over-quarter.
  • 0 funds opened new Theseus Pharmaceuticals, Inc. Common Stock positions in Q1 2024 and 69 closed out, a net change of -69 holders.
  • The largest Theseus Pharmaceuticals, Inc. Common Stock buyer in Q1 2024 was Goldman Sachs, an estimated $53.8K added.
  • The largest Theseus Pharmaceuticals, Inc. Common Stock seller in Q1 2024 was OrbiMed, an estimated $71.7M sold.

Based on aggregated 13F filings for Q1 2024.